India's Supreme Court has declared Bayer's case against cancer generics unsuccessful

Source: Ding Xiangyuan on December 15, 2014, Bayer, a German pharmaceutical manufacturer, tried to prevent the sale of its low-cost generic anti-cancer drug dojme in India through a lawsuit, but it was rejected by the Supreme Court on December 12 and failed to win the final fight The Supreme Court's decision upheld the previous ruling, which was seen as a blow to foreign-funded pharmaceutical companies, although global pharmaceutical companies have been trying to exclude Indian generic drugs from competing for their expensive drugs The Supreme Court rejected Bayer's challenge to the law, forcing companies to sell their generic drugs for kidney and liver cancer, according to Indian generic group NATCO Under the global trade-related intellectual property agreement, countries can force the sale of generic drugs for which most people cannot afford the cost However, Bayer has been struggling with this compulsory license, which it believes weakens the international patent system and is not conducive to drug research and development The German drugmaker expressed disappointment at the Supreme Court's decision, and its legal experts are evaluating the resolution "We are in the process of analyzing the final decision, which determines any subsequent action," a company spokesman said In 2012, the Patent Office of India granted NATCO the right to sell dojme generic drugs for the first time The price of a month's dose of generic drugs is 8800 rupees, which is only a small part of the price compared with Bayer's 280000 rupees Bayer questioned the decision for long-term operation Western pharmaceutical groups have had a long history of patent problems in India Many people in this country can't afford patent drugs, which has contributed to the booming of the country's generic pharmaceutical industry Last year, there was a higher-level case in which Novartis, a Swiss pharmaceutical company, was rejected by the Supreme Court of India in an attempt to win patent protection for its anticancer drug, Gleevec In recent years, Indian courts have also revoked patents for other international pharmaceutical companies, including Pfizer, Roche and Merck.